Overdose how excessive government regulation stifles pharmaceutical innovation
Epstein, Richard Allen
Overdose how excessive government regulation stifles pharmaceutical innovation - New Haven Yale University Press 2006 - xi, 283 p. 25 cm
"An Institute for Policy Innovation Book."
Includes bibliographical references (p. 241-271) and index.
Rising expectations-- and diminishing returns -- Property generally : externalities, coordination, and the public domain -- Intellectual property: the public domain and private rights -- Taming conflict of interests -- Federally sponsored research under Bayh-Dole -- The anticommons -- The single monopoly : current patent limitations -- Rate regulation : an unneeded swamp -- Patent purchases: a second swamp -- Socialization of R & D : the final swamp -- The steady expansion of FDA power -- FDA versus the individual : upstream or downstream decision making -- Drug withdrawal : too much, too soon -- Getting the drugs to market -- Deceptive marketing -- Tort preliminaries -- Product liability for prescription drugs : manufacturing and design cases -- The main event : misrepresentation, overpromotion, and duty to warn -- Conclusion : socialized medicines.
9780300116649
2006006514
GBA667981 bnb
101271119 DNLM 013526886 Uk
United States--Food and Drug Administration
Pharmaceutical industry--Government policy--United States
Drug Industry--United States
Government Regulation--United States
Public Policy--United States
HD9666.6 / .E67 2006
338.4761510973 / EP-O
QV 736 / E64o 2006
Overdose how excessive government regulation stifles pharmaceutical innovation - New Haven Yale University Press 2006 - xi, 283 p. 25 cm
"An Institute for Policy Innovation Book."
Includes bibliographical references (p. 241-271) and index.
Rising expectations-- and diminishing returns -- Property generally : externalities, coordination, and the public domain -- Intellectual property: the public domain and private rights -- Taming conflict of interests -- Federally sponsored research under Bayh-Dole -- The anticommons -- The single monopoly : current patent limitations -- Rate regulation : an unneeded swamp -- Patent purchases: a second swamp -- Socialization of R & D : the final swamp -- The steady expansion of FDA power -- FDA versus the individual : upstream or downstream decision making -- Drug withdrawal : too much, too soon -- Getting the drugs to market -- Deceptive marketing -- Tort preliminaries -- Product liability for prescription drugs : manufacturing and design cases -- The main event : misrepresentation, overpromotion, and duty to warn -- Conclusion : socialized medicines.
9780300116649
2006006514
GBA667981 bnb
101271119 DNLM 013526886 Uk
United States--Food and Drug Administration
Pharmaceutical industry--Government policy--United States
Drug Industry--United States
Government Regulation--United States
Public Policy--United States
HD9666.6 / .E67 2006
338.4761510973 / EP-O
QV 736 / E64o 2006